Gp100:209-217(210M) Explained

Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210.^[1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example).^{[2] [3]}

Clinical trials

It gave good results in a trial for advanced melanoma when used in combination with interleukin-2.^[4] Another trial against Ipilimumab in advanced melanoma suggested Ipilimumab may be better than the gp100 vaccine alone.^[5]

Notes and References

1. http://www.cancer.gov/drugdictionary/?CdrID=476335 NCI Drug Dictionary
2. http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=492712 NCI Drug Dictionary
3. Web site: Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma . 2010.
4. News: Vaccine shows promise in advanced melanoma -study . 30 May 2009 . Reuters.
5. Web site: BMS' Ipilimumab Proves Itself in Metastatic Melanoma Patients . 7 June 2010 .